Cop's hearing postponed - Danbury News Times

-
  • East Haven Police officer Vincent Ferrara Photo: Ken Dixon / Hearst Connecticut Media / Connecticut Post

    East Haven Police officer Vincent Ferrara

    East Haven Police officer Vincent Ferrara

    Photo: Ken Dixon / Hearst Connecticut Media

Photo: Ken Dixon / Hearst Connecticut Media

Image 1 of / 1

Caption

Close

Image 1 of 1

East Haven Police officer Vincent Ferrara

East Haven Police officer Vincent Ferrara

Photo: Ken Dixon / Hearst Connecticut Media

EAST HAVEN — A scheduled hearing on the suspension of a whistle-blowing cop was abruptly rescheduled Thursday to an unspecified date.

Few details were available Thursday night, but Police Officer Vincent Ferrara, whose 2011 testimony led to the arrest and imprisonment of four cops for a campaign of harassment and intimidation, said he was told by his legal team that the hearing with Police Chief Edward Lennon, scheduled to gauge his fitness for returning to work after nearly a year, was postponed.

Both Ferrara’s attorneys and Stephen Sedor, a lawyer for the town, did not return calls for comment Thursday night. Ferrara was diagnosed with a brain tumor about a year ago, shortly after he was put on a paid suspension over a disciplinary issue involving the use of the police department’s email server. A recent letter from Ferrara’s neurosurgeon said he was fit to return to work.

Ferrara is also suing the town over alleged retribution tactics in connection with the federal investigation into the abuse of Latinos.

kdixon@ctpost.com Twitter: @KenDixonCT



https://ift.tt/2Sk8XUp

Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n
Read more